You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it. In addition as per local health authority Regulations, some of our products are not approved for sales, marketing or distribution in all countries.
Kedrion Biosc - Front Image


  1. 15-03-2021

    Annual Results 2020

    Kedrion reaches a Turnover of EUR 697.2 and, despite COVID-19, raises to 13.8% its Reported EBITDA at EUR 95.9 million

    read more 
  2. 01-09-2020

    KEDPLASMA GmbH changes its name to Kedrion Biopharma GmbH

    Further step towards an even stronger focus on patients in Europe

    read more 
  3. 21-07-2020

    COVID-19. Kedrion partners with Columbia University Irving MC

    Kedrion and Columbia University release video statements

    read more 
  4. 07-04-2020

    Coronavirus, from Plasma an anti Covid-19 treatment

    Kedrion’s commitment to find a treatment from convalescent patient plasma

    read more 


For more information please contact: [email protected]